NICE backs EGFR-mutation diagnostics from Roche, Qiagen

The U.K.'s NICE issued EGFR mutations in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC). NICE backed the cobas EGFR Mutation Test from Roche (SIX:ROG; OTCQX:RHHBY) and the therascreen EGFR RGQ PCR Kit from Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), along with three sequencing methods. ...